Busilong Pharmaceuticals: Holding subsidiary intends to transfer 60% equity of Hunan Zhongce for 1 yuan.

Changsheng Pharmaceutical announced that its holding subsidiary Changsheng Medical Diagnosis intends to transfer 60% of its equity in Hunan Zhongce through 1 yuan to Yang Futai. After the transfer is completed, Changsheng Medical Diagnosis will no longer hold equity in Hunan Zhongce. As of December 31, 2025, the net assets of Hunan Zhongce were -450,300 yuan, the revenue for the year 2025 was 1,075,700 yuan, and the net loss was 1,024,100 yuan. This transaction does not constitute a related party transaction or a major asset restructuring, does not require a shareholder meeting for approval, and will not have a significant adverse impact on the company's finances and operations.